Combination Chemotherapy for Rhabdomyosarcoma
Trial Summary
What is the purpose of this trial?
This phase III trial compares the safety and effect of adding vinorelbine to vincristine, dactinomycin, and cyclophosphamide (VAC) for the treatment of patients with high risk rhabdomyosarcoma (RMS). High risk refers to cancer that is likely to recur (come back) after treatment or spread to other parts of the body. This study will also examine if adding maintenance therapy after VAC therapy, with or without vinorelbine, will help get rid of the cancer and/or lower the chance that the cancer comes back. Vinorelbine and vincristine are in a class of medications called vinca alkaloids. They work by stopping cancer cells from growing and dividing and may kill them. Dactinomycin is a type of antibiotic that is only used in cancer chemotherapy. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Vinorelbine, vincristine, dactinomycin and cyclophosphamide are chemotherapy medications that work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may have the potential to eliminate rhabdomyosarcoma for a long time or for the rest of patient's life.
Will I have to stop taking my current medications?
The trial does not specify if you must stop taking your current medications, but you cannot have taken certain drugs that affect liver enzymes (CYP3A4 inhibitors and inducers) within 7 days before joining. If you're on chemotherapy for non-cancer conditions, you must stop it before starting the trial.
What data supports the effectiveness of the drug combination used in the clinical trial for rhabdomyosarcoma?
Research shows that the combination of vinorelbine and low-dose cyclophosphamide has been used successfully in treating pediatric sarcomas, and the VAC regimen (vincristine, dactinomycin, and cyclophosphamide) has shown improved survival rates in low-risk rhabdomyosarcoma patients. Additionally, the VIVA regimen, which includes vinorelbine, has demonstrated significant responses in high-risk rhabdomyosarcoma patients.12345
Is the combination chemotherapy for rhabdomyosarcoma safe for humans?
The combination chemotherapy for rhabdomyosarcoma, which includes drugs like cyclophosphamide, dactinomycin, and vinorelbine, has been studied in various trials. While patients often experience some side effects like hematological toxicity (blood-related side effects), major complications are rare, and the treatment is generally considered feasible and safe for use in humans.13456
What makes the combination chemotherapy for rhabdomyosarcoma unique?
Research Team
Wendy Allen-Rhoades
Principal Investigator
Children's Oncology Group
Eligibility Criteria
This trial is for patients up to 50 years old with high-risk rhabdomyosarcoma (RMS), including embryonal and alveolar types, but not adult-type pleomorphic. Eligible participants must have newly diagnosed RMS, meet specific stage and group criteria, have a certain kidney function level, normal bilirubin levels unless obstructed by tumor, and provide informed consent. Pregnant or breastfeeding women are excluded as well as those with uncontrolled infections or central nervous system involvement of RMS.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients receive chemotherapy with vincristine, dactinomycin, and cyclophosphamide (VAC) or vinorelbine, dactinomycin, and cyclophosphamide (VINO-AC) for up to 14 cycles, with radiation therapy on weeks 13 and 40
Maintenance
Patients receive maintenance therapy with vinorelbine and oral cyclophosphamide for up to 6 cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Cyclophosphamide
- Dactinomycin
- Vinorelbine Tartrate
Cyclophosphamide is already approved in United States, European Union, Canada, Japan for the following indications:
- Breast cancer
- Ovarian cancer
- Multiple myeloma
- Leukemia
- Lymphoma
- Rheumatoid arthritis
- Breast cancer
- Ovarian cancer
- Multiple myeloma
- Leukemia
- Lymphoma
- Rheumatoid arthritis
- Breast cancer
- Ovarian cancer
- Multiple myeloma
- Leukemia
- Lymphoma
- Rheumatoid arthritis
- Breast cancer
- Ovarian cancer
- Multiple myeloma
- Leukemia
- Lymphoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Oncology Group
Lead Sponsor
National Cancer Institute (NCI)
Collaborator